Mesoblast Limited MESO
12.45 USD -0.82 (-6.18%)
Regular-session close
12.45 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
12.40 Day range 13.02
11.95 52-week range 20.96
- YTD
- -30.99%
- 1 year
- -15.71%
News
globenewswire.com Mesoblast Showcased at ASX Premier Investor Day Event NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at…
marketbeat.com Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026 and said it expects a pivotal trial readout for its experimental chronic low back pain treatment around midyear to the…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket Glaukos surged 17.4% premarket after strong Q3 results and raised FY26 sales guidance; INLF, NCPL and PCLA also rallied.
